PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 2025Batna Journal of Medical Sciences (BJMS)0 citations

Lung Cancer in Non-Smokers. Prospective descriptive study of a cohort of 68 patients.

View Full Paper
ZYZaim YOUNSIHôpital Militaire Moulay IsmailABAlaeddine BerkaneUniversité des Sciences et de la Technologie d'Oran Mohamed BoudiafYBYoucef BOUCHEHAMHôpital Militaire Moulay Ismail

Key Points

  • Lung cancer in never smokers often presents with passive smoking exposure, particularly in women.
  • Adenocarcinoma is the most common type found, accounting for 75% of cases with a notable EGFR mutation rate of 34%.
  • Most patients were diagnosed at stage IV and received systemic treatment, achieving an overall survival rate of 15.4 months.
  • The study highlights non-tobacco-related risk factors associated with lung cancer, emphasizing the need for further research.

Abstract

Introduction: Lung cancer in never smokers (LCINS) is considered as a separate entity given its epidemiological specificities. Materials and methods: This is a prospective multi-centric epidemiological study of 68 patients treated and followed for LCINS (less than 100 cigarettes during all lifetime). Its main objective was to describe clinical features, molecular somatic profile, the risk-factors exposure, and survey in never smokers. Results: Between juin2017 and februry2019 a cohort of 60 (88%) women and 08 (12%) men was collected, with a median age of 59 years.Two-third were exposed to passive smoking (mainly women and in domestic setting). Domestic use of biofuels is present in 43% of cases and the exposure to cooking oil is almost present in women, with median duration of 10 years. The frequent common symptom is cough in 43% of cases. Thoracic CT found opacity in 94% cases ; peripheral topography is present in 63% of cases. Adenocarcinoma is found in 75% of cases, and the EGFR mutation is present in 34% of cases. The majority of patients are classified as stage IV (74%), systemic treatment is used in 98% of cases. After follow-up time of 10 months, the therapeutic results are marked by objective response in 44% of cases; radiological stability is maintained in 41% of cases. Overall survival is 15,4 months with extremes of 03 and 24 months. Conclusion: LCINS is an interesting entity for the study of nontobacco-related cancer risk factors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

YOUNSI et al. (2025) studied this question.

synapsesocial.com/papers/68d4539c31b076d99fa594d0https://doi.org/10.48087/bjmsoa.2025.12303
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances2026 · 7 citations
  2. 2Abstract LB231: The mutagenic forces shaping the genomic landscape of lung cancer in never smokers2024 · 1 citations
  3. 3Abstract 1302: Distinct Histology of Lung Cancer inpeople who have never smokedand Prognostic Determinants in Non-Mucinous Adenocarcinoma.2026
  4. 4Primary Lung Cancer in Non-Smoking Women: A Retrospective Analysis at CHU Hassan II, Fez2025
  5. 5Observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE): study protocol2026